Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
S.E. Gabriel.
The epidemiology of rheumatoid arthritis.
Rheum Dis Clin North Am, 27 (2001), pp. 269-281
[2.]
Guidelines for the Management of Rheumatoid Arthritis.
2002 Update.
Arthritis Rheum, 46 (2002), pp. 328-346
[3.]
M.H. Pillinger, S.B. Abramson.
The neutrophil in rheumatoid arthritis.
Rheum Dis Clin North Am, 21 (1995), pp. 691-714
[4.]
J.L. Masferrer, B.S. Zweifel, P.T. Manning, S.D. Hauser, K.M. Leahy, W.G. Smith, et al.
Selective inhibition of inducible cycloxigenase-2 in inlammation and pain.
Proc Natl Acad Sci USA, 91 (1994), pp. 3229-3232
[5.]
G.D. Anderson, S.D. Hauser, K.L. McGarity, M.E. Bremer, P.C. Isakson, S.A. Gregory.
Selective inhibition of cyclooxigenase(COX)-2 reverse inflammation and expression of COX-2 and IL-6 in rat adjuvant arthritis.
J Clin Invest, 97 (1996), pp. 2672-2679
[6.]
I. Siegle, T. Klein, J.T. Backman.
Expression of cyclooxigenase 1 and cyclooxigenase 2 in human synovial tissue:differential elevation of cycloxigenas 2 in inflammatory joints diseases.
Arthritis Rheum, 41 (1998), pp. 122-129
[7.]
J. Martel-Pelletier, J.P. Pelletier, H. Fahmi.
Cyclooxigenase–2 and prostaglandins in articular tissues.
Sem Arthritis Rheum, 33 (2003), pp. 155-167
[8.]
L. Lavagno, G. Gunella, C. Bardelli, S. Spina, L.G. Fresu, I. Viano, et al.
Antiinflammatory drugs and tumor necrosis factor alfa production from monocytes: role of transcription factor NF-kB and implication for rheumatoid arthritis therapy.
Eur J Pharmacol, 501 (2004), pp. 199-208
[9.]
A. Kajander, J. Martio.
Diclofenac Sodium and Naproxen in the treatment of rheumatoid arthritis: a comparative double blind study.
Scan J Rheumatol, 22 (1978), pp. S57-S62
[10.]
E.P. Gall, E.M. Caperton, J.E. McComb, R. Messner, C.V. Multz, M. O’Hanlan, et al.
Clinical comparison of ibuprofen, fenoprofen calcium, naproxen and tolmetin sodium in rheumatoid arthritis.
J Rheumatol, 9 (1982), pp. 402-407
[11.]
W.D. Burton, B.L. Hazleman.
Fenbufen and indomethacin: a comparative study in rheumatoid arthritis.
Clin Ther, 5 (1983), pp. 260-267
[12.]
A.L. Kolodny.
Two double blind trials of diclofenac sodium with aspirin and with naproxen in the treatment of patients with rheumatoid arthritis.
J Rheumatol, 15 (1988), pp. 1205-1211
[13.]
T.G. Osborn, R.L. Parks, T.L. Moore.
Diflunisal vs naproxen in the management of rheumatoid arthritis.
Clin Ther, 11 (1989), pp. 737-743
[14.]
B.J. Lister, M. Poland, R.E. De Lapp.
Efficacy of nabumetone vs diclofenac,ibuprofen and piroxicam in osteoarthritis and rheumatoid arthritis.
Am J Med, 95 (2003), pp. 25-95
[15.]
S. Garner, D. Fidan, R. Frankish, M. Judd, B. Shea, T. Towheed, et al.
Celecoxib para la artritis reumatoide (revisión Cochrane traducida).
La Biblioteca Cochrane Plus, Update Sofware Ltd, (2005),
[16.]
P. Emery, H. Zeidler, T.K. Kvien, M. Guslandi, R. Naudin, H. Stead, et al.
Celecoxib vs diclofenac in long term management of rheumatoid arthritis: randomized double-blind comparison.
Lancet, 354 (1999), pp. 2106-2111
[17.]
S. Garner, D. Fidan, R. Frankish, M. Judd, T. Towheed, G. Wells, et al.
Rofecoxib para la artritis reumatoide (revisión Cochrane traducida).
La Biblioteca Cochrane Plus, Update Software Ltd, (2004),
[18.]
E. Collantes, S.P. Curtis, K. Wing Lee, N. Casas, T. McCarthy, A. Melian, et al.
A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
BMC Family Practice, 3 (2002), pp. 10
[19.]
A. Matsumoto, A. Melian, D.R. Mandel, H.H. McIlwain, D. Borenstein, P.L. Zhao, et al.
A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid artritis.
J Rheumatol, 29 (2002), pp. 1623-1630
[20.]
J.E. Edwards, H.J. McQuay, R.A. Moore.
Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis:systematic review of randomized controlled trials.
Pain, 111 (2004), pp. 286-296
[22.]
F. Wolfe, S. Zhao, N. Lane.
Preferencefor nonsteroidal antiinflammatory drug over acetaminophen by rheumatic disease patients: a survey of 1799 patients with osteoarthritis, rheumatoid arthritis and fibromyalgia.
Arthritis Rheum, 44 (2001), pp. 2451-2455
[23.]
T. Wienecke, P.C. Goetzshe.
Paracetamol vs aines para la artritis reumatoide( Revisión Cochrane traducida).
La Biblioteca Cochrane Plus, Update Software Ltd, (2005),
[24.]
E.H. Choy, D.L. Scott, G.H. Kingsley, P. Williams, J. Wojtulewski, G. Papasavvas, et al.
Treating rheumatoid artritis early with disease modifying drugs reduces joint damage: a randomized double blind trial of sulphaslazine vs diclofenac sodium.
Clin Exp Rheum, 20 (2002), pp. 351-358
[25.]
H.E. Paulus, D. Di Primeo, J.T. Sharp, H.K. Genant, B.N. Weissman, M.H. Weisman, et al.
Patient retention and hand-wrist radiograph progression of rheumatoid arthritis during a 3 year propective study that prohibited disease modifying antirheumatic drugs.
J Rheumatol, 31 (2004), pp. 470-481
[26.]
Scottish Intercollegiate Guidelines Network. Management of early rheumatoid arthritis. A National Clinical Guideline. December 2000.
[27.]
National Institute for Clinical Excellence. Guidance on the use of cyclooxygenase( Cox)II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. May 2004.
[28.]
Grupo GUIPCAR.
Guía de práctica clínica para el manejo de la artritis reumatoide en España.
Sociedad Española de Reumatología, (2001),
Copyright © 2006. Elsevier España S.L. Barcelona
